Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Equity Average (2018 - 2025)

Serina Therapeutics' Equity Average history spans 8 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Equity Average rose 111.27% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, up 111.27%, while the annual FY2024 figure was -$15.9 million, 54.64% up from the prior year.
  • Equity Average for Q3 2025 was $1.7 million at Serina Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.7 million in Q3 2025 and bottomed at -$36.9 million in Q1 2023.
  • The 5-year median for Equity Average is -$12.4 million (2022), against an average of -$16.2 million.
  • The largest annual shift saw Equity Average crashed 612.89% in 2021 before it skyrocketed 111.27% in 2025.
  • A 5-year view of Equity Average shows it stood at -$10.9 million in 2021, then tumbled by 142.2% to -$26.5 million in 2022, then decreased by 24.02% to -$32.8 million in 2023, then skyrocketed by 79.71% to -$6.7 million in 2024, then soared by 125.57% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Equity Average are $1.7 million (Q3 2025), $1.6 million (Q2 2025), and $1.0 million (Q1 2025).